medigraphic.com
ISSN 1029-3043 (Electronic)

2016, Number 4

<< Back Next >>

Medicentro 2016; 20 (4)

Treatment results in patients with ovarian cancer during 2001-2013

Brito DY, Caravia BF, Hernández DD, González AAG, Massip NJ

Language: Spanish
References: 13
Page: 259-267
PDF size: 223.34 Kb.


ABSTRACT

Introduction: ovarian cancer has a high mortality and constitutes the first cause of death from gynecological cancer; it is only preceded by breast cancer although its frequency is lower than other uterine cancers.
Objective: to describe types of treatments performed, their results in this group of patients and their relationship to histology and tumor stages.
Methods: an observational, retrospective study of 98 patients with ovarian cancer was carried out at the «Ramón González Coro» Gyneco-Obstetric Teaching Hospital from 2001 to 2013. Data were collected from their medical records. Chi-square test of association was used, and p ‹ 0.05 was considered statistically significant.
Results: a number of 45 (67.5 %) received five and six cycles of chemotherapy, with a median of six from the 80 patients who received it after surgery. The most used combination was carboplatin and taxol in 36 (45.0 %). The highest percentages of complete optimal surgical resection were focused on patients with epithelial and stromal tumors: 52.1 % and 52.6 % respectively, as well as, in patients with stage I disease: 22 (68.8 %) with significant association. In 36 (37.1 %) of the operated patients was indication of interval surgery. The 44 (45.4 %) had a disease relapse.
Conclusions: the primary therapeutic option was surgery with relatively high percentages of complete resection and optimal intervention. The most commonly used chemotherapy was the combination of platinum and taxol. There was no significant association between treatments and types of cancer.


REFERENCES

  1. Redondo Sánchez A, Castelo Fernández B, Gómez Raposo C, Cruz Castellanos P. Cáncer de ovario. Medicine-Programa de Formación Médica Continuada Acreditado [internet]. 2013 mar. [citado 10 ago. 2015];11(27):àprox. 8 p.]. Disponible en: http://www.sciencedirect.com/science/article/pii/S0304541213705183

  2. Pons Porrata LM, García Gómez O, Salmon Cruzata A, Macías Navarro MM, Guerrero Fernández CM. Tumores de ovario: patogenia, cuadro clínico, diagnóstico ecográfico e histopatológico. MEDISAN [internet]. 2012 jun. [citado 10 ago. 2014];16(6):[aprox. 12 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029- 30192012000600013&lng=es

  3. Valdivia Ponce JE. Cáncer de ovario. Rev Peruana Ginecol Obstet [internet]. 1967 dic. [citado 20 abr. 2015];13(3):[aprox. 13 p.]. Disponible en: http://www.spog.org.pe/web/revista/index.php/RPGO/article/view/867/824

  4. Cheroni GP, Saike GD, Navarro VL, Giarmaná MJ. Cáncer de ovario. Hosp Aeronáut Central [internet]. 2012 [citado 20 abr. 2015];7(1):[aprox. 5 p.]. Disponible en: http://www.hac.mil.ar/publicaciones/revismedic/0701/16-20.pdf

  5. Rodríguez Reigosa JE, Guerrero García LP, Esperón Noa RP, Linchenat Lambert A, Silveira Pablos JM, Díaz Ortega I, et al. Cáncer de ovario en el Instituto Nacional de Oncología y Radiobiología de Cuba: 2001 a 2005. Rev Cubana Cir [internet]. 2009 [citado 20 abr. 2015];48(1):[aprox. 7 p.]. Disponible en: http://www.bvs.sld.cu/revistas/cir/vol48_1_09/cir08109.htm

  6. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up on Behalf of the ESMO Guidelines Working Group; 2010.

  7. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, et al. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv [internet]. 2015 Aug. [citado 20 oct. 2015];10(2):[aprox. 10 p.]. Disponible en: http://link.springer.com/article/10.1007%2Fs11764-015-0472-9

  8. Casanova AV, Sánchez SR. Cáncer de ovario. Epidemiología y aspectos clínicos. Rev Peruana Ginecol Obstet [internet]. 2015 [citado 20 ago. 2015];26(1):[aprox. 7 p.]. Disponible en: http://108.163.168.202/web/revista/index.php/RPGO/article/view/1623/1576

  9. Pignata S, Cannella L, Leopardo D, Pisano C, Salvatore Bruni G, Facchini G. Chemotherapy in epithelial ovarian cancer. Cancer Letters. 2011;303:73-83.

  10. Yao-An S, Wai-Hou L, Po-Hung C, Chun-Lin H, Yen-Hou C, Chi-Mu C. Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol(®)-resistant ovarian cancer. Am J Transl Res [internet]. 2015 May 15 [citado 20 ago. 2015];7(5):[aprox. 15 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494136/

  11. Morrison J, Haldar K, Kehoe S, Lawrie TA. Quimioterapia versus cirugía para el tratamiento inicial del cáncer epitelial de ovario avanzado. Cochrane Database of Systematic Reviews [internet]. 2012 ago. 15 [citado 20 oct. 2015];(8):[aprox. 5 p.]. Disponible en: http://es.summaries.cochrane.org/CD005343/quimioterapia-versus-cirugia-para-el-tratamientoinicial- del-cancer-epitelial-de-ovario-avanzado

  12. Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121:615-9.

  13. Valdivia Ponce JE, Galdós HR. Resultados del tratamiento en el cáncer de ovario. Rev Peruana Ginecol Obstet [internet]. 1962 [citado 20 ago. 2015];8(3):[aprox. 10 p.]. Disponible en: http://108.163.168.202/web/revista/index.php/RPGO/article/view/735/696




2020     |     www.medigraphic.com